Business Description
BridgeBio Oncology Therapeutics Inc
NAICS : 541713
SIC : 2836
ISIN : US1079241022
Total Employee Number:
106Description
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 95.41 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.06 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.75 | |||||
9-Day RSI | 60.24 | |||||
14-Day RSI | 54.22 | |||||
3-1 Month Momentum % | -12.35 | |||||
6-1 Month Momentum % | -32.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.16 | |||||
Quick Ratio | 6.16 | |||||
Cash Ratio | 5.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -96.03 | |||||
ROA % | -46.64 | |||||
ROIC % | -390.99 | |||||
ROC (Joel Greenblatt) % | -5111.73 | |||||
ROCE % | -56.79 | |||||
Moat Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.81 | |||||
Price-to-Tangible-Book | 1.81 | |||||
EV-to-EBIT | -2.51 | |||||
EV-to-Forward-EBIT | -2.33 | |||||
EV-to-EBITDA | -2.52 | |||||
EV-to-FCF | -3.25 | |||||
| Price-to-Net-Current-Asset-Value | 3.04 | |||||
| Price-to-Net-Cash | 3.26 | |||||
Earnings Yield (Greenblatt) % | -39.84 | |||||
FCF Yield % | -19.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBOT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BridgeBio Oncology Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -527.989 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 54.22 | ||
| 14-Day ATR ($) | 0.516168 | ||
| 20-Day SMA ($) | 7.66 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 7 - 14.87 | ||
| Shares Outstanding (Mil) | 80.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BridgeBio Oncology Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BridgeBio Oncology Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 29 days | ||
| General meeting for 2026 | 2026-06-16 13:00 | 7.73 (-0.90%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 8.33 (-0.24%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 8.33 (-0.24%) | ||
| Annual report for 2025 | 2026-03-05 | 10.17 (+4.31%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-24 16:30 | 10.15 (+2.22%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 10.15 (+2.22%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-12 17:15 | 13.19 (-5.31%) |
Show
Entries
BridgeBio Oncology Therapeutics Inc Frequently Asked Questions
What is BridgeBio Oncology Therapeutics Inc(BBOT)'s stock price today?
The current price of BBOT is $8.40. The 52 week high of BBOT is $14.87 and 52 week low is $7.00.
When is next earnings date of BridgeBio Oncology Therapeutics Inc(BBOT)?
The next earnings date of BridgeBio Oncology Therapeutics Inc(BBOT) is 2026-08-05 Est..
Does BridgeBio Oncology Therapeutics Inc(BBOT) pay dividends? If so, how much?
BridgeBio Oncology Therapeutics Inc(BBOT) does not pay dividend.
Guru Commentaries on NAS:BBOT
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on BridgeBio Oncology Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers